Ensysce Biosciences, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 10.61 million compared to USD 24.17 million a year ago. Basic loss per share from continuing operations was USD 4.69 compared to USD 139.42 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5842 USD | +6.86% | +2.31% | -44.89% |
Mar. 21 | Transcript : Ensysce Biosciences, Inc., Q4 2023 Earnings Call, Mar 21, 2024 | |
Mar. 15 | Ensysce Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.89% | 4.43M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ENSC Stock
- News Ensysce Biosciences, Inc.
- Ensysce Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023